The Hematology segment focuses on the discovery, development, and commercialization of small molecule drugs to treat hematologic disorders. Rigel's lead product, TAVALISSE (fostamatinib), is an oral spleen tyrosine kinase (SYK) inhibitor approved for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Research and development activities include ongoing clinical trials for fostamatinib in warm autoimmune hemolytic anemia (wAIHA) and hospitalized COVID-19 patients. The segment leverages advanced medicinal chemistry and clinical trial expertise to address unmet medical needs in blood disorders, aiming to improve patient outcomes and quality of life. Market positioning is strengthened through strategic partnerships and collaborations, such as the license agreement with Kissei Pharmaceutical Co., Ltd. for TAVALISSE in Japan and other Asian countries. Future opportunities include expanding the label for TAVALISSE and advancing other pipeline candidates.

The Oncology segment is dedicated to developing innovative therapies for various cancers. Rigel's research efforts include the development of R289, an oral interleukin receptor associated kinase 1/4 (IRAK1/4) inhibitor, currently in Phase I clinical trials for autoimmune, inflammatory, and hematology-oncology diseases. The company also has a collaboration with Daiichi Sankyo to develop murine double minute 2 (MDM2) inhibitors for solid and hematological malignancies. The segment utilizes advanced drug discovery platforms and clinical trial expertise to target cancer pathways and improve patient outcomes. Market positioning is enhanced through strategic partnerships and collaborations, such as the agreement with BerGenBio AS for the development and commercialization of AXL inhibitors in oncology. Future opportunities include expanding the oncology pipeline and advancing clinical trials for R289 and other potential drug candidates.

This segment focuses on developing treatments for rare immune diseases and conditions with high unmet medical needs. Rigel is developing fostamatinib for warm autoimmune hemolytic anemia (wAIHA), currently in a Phase III clinical trial. The company is also developing R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, which has completed Phase I clinical trials for autoimmune and inflammatory diseases. The segment leverages expertise in immunology and drug development to address diseases with limited treatment options. Market positioning is strengthened through collaborations, such as the strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases. Future opportunities include expanding the pipeline with novel therapies for rare diseases and advancing clinical trials for R552 and fostamatinib.